Skip to main content

Choosing Among PARP Inhibitors as Maintenance Therapy in Ovarian Cancer

Videos — September 8, 2020
Amina Ahmed, MD
Associate Chief Medical Officer
Division Gynecology, Dept OBGYN
Cancer Center of Rush University Medical Center
Chicago, IL
Paula Anastasia, RN, MN, AOCN
GYN Oncology Clinical Nurse Specialist
UCLA Health
Los Angeles, CA
Ali McBride, PharmD, MS
Clinical Coordinator
The University of Arizona Cancer Center
Tucson, AZ
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, describe their experiences in the use of niraparib, olaparib, and rucaparib as first-line maintenance therapy in ovarian cancer.

Related Items